AstraZeneca To Stop 340B Discounts Via Contract Pharmacies

AstraZeneca is the latest drug maker to tell providers it plans to end 340B pricing for contract pharmacies, with few exceptions, a move that 340B Health called a serious escalation of an ongoing trend and said, if HHS doesn’t step in, the group will turn to Congress for help or take the drug manufacturers to court. In a letter to 340B participants obtained by Inside Health Policy , AstraZeneca says that beginning Oct. 1 it will no longer follow the...